37 results on '"Orecchini, E"'
Search Results
2. Human Indoleamine 2,3-dioxygenase 1 (IDO1) Expressed in Plant Cells Induces Kynurenine Production.
- Author
-
Bellucci, M, Pompa, A, De Marcos Lousa, C, Panfili, E, Orecchini, E, Maricchiolo, E, Fraternale, D, Orabona, C, De Marchis, F, Pallotta, MT, Bellucci, M, Pompa, A, De Marcos Lousa, C, Panfili, E, Orecchini, E, Maricchiolo, E, Fraternale, D, Orabona, C, De Marchis, F, and Pallotta, MT
- Abstract
Genetic engineering of plants has turned out to be an attractive approach to produce various secondary metabolites. Here, we attempted to produce kynurenine, a health-promoting metabolite, in plants of Nicotiana tabacum (tobacco) transformed by Agrobacterium tumefaciens with the gene, coding for human indoleamine 2,3-dioxygenase 1 (IDO1), an enzyme responsible for the kynurenine production because of tryptophan degradation. The presence of IDO1 gene in transgenic plants was confirmed by PCR, but the protein failed to be detected. To confer higher stability to the heterologous human IDO1 protein and to provide a more sensitive method to detect the protein of interest, we cloned a gene construct coding for IDO1-GFP. Analysis of transiently transfected tobacco protoplasts demonstrated that the IDO1-GFP gene led to the expression of a detectable protein and to the production of kynurenine in the protoplast medium. Interestingly, the intracellular localisation of human IDO1 in plant cells is similar to that found in mammal cells, mainly in cytosol, but in early endosomes as well. To the best of our knowledge, this is the first report on the expression of human IDO1 enzyme capable of secreting kynurenines in plant cells.
- Published
- 2021
3. Discovery of Highly Potent Benzimidazole Derivatives as Indoleamine 2,3-Dioxygenase-1 (IDO1) Inhibitors: From Structure-Based Virtual Screening to in Vivo Pharmacodynamic Activity
- Author
-
Serafini, M, Torre, Enza, Aprile, S, Grosso, Ed, Gesù, A, Griglio, A, Colombo, G, Travelli, C, Paiella, S, Adamo, A, Orecchini, E, Coletti, A, Pallotta, Mt, Ugel, S, Massarotti, A, Pirali, T, Fallarini, S., Torre E (ORCID:0000-0001-6754-2611), Serafini, M, Torre, Enza, Aprile, S, Grosso, Ed, Gesù, A, Griglio, A, Colombo, G, Travelli, C, Paiella, S, Adamo, A, Orecchini, E, Coletti, A, Pallotta, Mt, Ugel, S, Massarotti, A, Pirali, T, Fallarini, S., and Torre E (ORCID:0000-0001-6754-2611)
- Abstract
In this study, a successful medicinal chemistry campaign that exploited virtual, biophysical, and biological investigations led to the identification of a novel class of IDO1 inhibitors based on a benzimidazole substructure. This family of compounds is endowed with an extensive bonding network in the protein active site, including the interaction with pocket C, a region not commonly exploited by previously reported IDO1 inhibitors. The tight packing of selected compounds within the enzyme contributes to the strong binding interaction with IDO1, to the inhibitory potency at the low nanomolar level in several tumoral settings, and to the selectivity toward IDO1 over TDO and CYPs. Notably, a significant reduction of L-Kyn levels in plasma, together with a potent effect on abrogating immunosuppressive properties of MDSC-like cells isolated from patients affected by pancreatic ductal adenocarcinoma, was observed, pointing to this class of molecules as a valuable template for boosting the antitumor immune system.
- Published
- 2020
4. Novel HBsAg mutations correlate with hepatocellular carcinoma, hamper HBsAg secretion and promote cell proliferation in vitro
- Author
-
Salpini, R, Surdo, M, Warner, N, Cortese, MF, Colledge, D, Soppe, S, Bellocchi, MC, Armenia, D, Carioti, L, Continenza, F, Di Carlo, D, Saccomandi, P, Mirabelli, C, Pollicita, M, Longo, R, Romano, S, Cappiello, G, Spano, A, Trimoulet, P, Fleury, H, Vecchiet, J, Iapadre, N, Barlattani, A, Bertoli, A, Mari, T, Pasquazzi, C, Missale, G, Sarrecchia, C, Orecchini, E, Michienzi, A, Andreoni, M, Francioso, S, Angelico, M, Verheyen, J, Ceccherini-Silberstein, F, Locarnini, S, Perno, CF, Svicher, V, Salpini, R, Surdo, M, Warner, N, Cortese, MF, Colledge, D, Soppe, S, Bellocchi, MC, Armenia, D, Carioti, L, Continenza, F, Di Carlo, D, Saccomandi, P, Mirabelli, C, Pollicita, M, Longo, R, Romano, S, Cappiello, G, Spano, A, Trimoulet, P, Fleury, H, Vecchiet, J, Iapadre, N, Barlattani, A, Bertoli, A, Mari, T, Pasquazzi, C, Missale, G, Sarrecchia, C, Orecchini, E, Michienzi, A, Andreoni, M, Francioso, S, Angelico, M, Verheyen, J, Ceccherini-Silberstein, F, Locarnini, S, Perno, CF, and Svicher, V
- Abstract
BACKGROUND: An impaired HBsAg-secretion can increase HBV oncogenic-properties. Here, we investigate genetic-determinants in HBsAg correlated with HBV-induced hepatocellular carcinoma (HCC), and their impact on HBsAg-secretion and cell-proliferation. METHODS: This study included 128 chronically HBV-infected patients: 23 with HCC (73.9% D; 26.1% A HBV-genotype), and 105 without cirrhosis/HCC (72.4% D, 27.6% A) as reference-group. The impact of mutations on HBsAg-secretion was assessed by measuring the ratio [secreted/intracellular HBsAg] until day 5 post-transfection. The impact of mutations on cell-cycle advancement was assessed by flow-cytometry. RESULTS: Two HBsAg mutations significantly correlated with HCC: P203Q (17.4% [4/23] in HCC vs 1.0% [1/105] in non-HCC, P=0.004); S210R (34.8% [8/23] in HCC vs 3.8% [4/105] in non-HCC, P <0.001); P203Q+S210R (17.4% [4/23] in HCC vs 0% [0/110] in non-HCC, P=0.001). Both mutations reside in trans-membrane C-terminal domain critical for HBsAg-secretion. In in-vitro experiments, P203Q, S210R and P203Q+S210R significantly reduced the ratio [secreted/intracellular HBsAg] compared to wt at each time-point analysed (P <0.05), supporting an impaired HBsAg-secretion. Furthermore, P203Q and P203Q+S210R increased the percentage of cells in S-phase compared to wt, indicating cell-cycle progression (P203Q:26±13%; P203Q+S210R:29±14%; wt:18%±9, P <0.01. Additionally, S210R increased the percentage of cells in G2/M-phase (26±8% for wt versus 33±6% for S210R, P <0.001). CONCLUSIONS: Specific mutations in HBsAg C-terminus significantly correlate with HBV-induced HCC. They hamper HBsAg-secretion and are associated with increased cellular proliferation, supporting their involvement in HCC-development. The identification of viral genetic markers associated with HCC is critical to identify patients at higher HCC-risk that may deserve intensive liver monitoring, and/or early anti-HBV therapy.
- Published
- 2017
5. Adar1 restricts line-1 retrotransposition
- Author
-
Orecchini, E
- Subjects
Settore MED/04 - Patologia Generale ,Settore BIO/19 - Microbiologia Generale - Published
- 2016
6. HBsAg mutations correlated with HCC in vivo affect HBsAg release and favor cell proliferation in vitro
- Author
-
Salpini, R., primary, Surdo, M., additional, Warner, N., additional, Cortese, M.F., additional, Mirabelli, C., additional, Colledge, D., additional, Soppe, S., additional, Saccomandi, P., additional, Pollicita, M., additional, Longo, R., additional, Romano, S., additional, Cappiello, G., additional, Spanò, A., additional, Trimoulet, P., additional, Fleury, H., additional, Vecchiet, J., additional, Iapadre, N., additional, Barlattani, A., additional, Bertoli, A., additional, Mari, T., additional, Pasquazzi, C., additional, Missale, G., additional, Sarrecchia, C., additional, Orecchini, E., additional, Michienzi, A., additional, Andreoni, M., additional, Francioso, S., additional, Angelico, M., additional, Ceccherini-Silberstein, F., additional, Locarnini, S., additional, Perno, C.F., additional, and Svicher, V., additional
- Published
- 2016
- Full Text
- View/download PDF
7. P0614 : Key HBsAg mutations significantly correlate with HCC, hamper HBsAg secretion and promote cell proliferation in vitro
- Author
-
Surdo, M., primary, Salpini, R., additional, Warner, N., additional, Cortese, M.F., additional, Mirabelli, C., additional, Colledge, D., additional, Soppe, S., additional, Pollicita, M., additional, Longo, R., additional, Romano, S., additional, Cappiello, G., additional, Spanò, A., additional, Trimoulet, P., additional, Fleury, H., additional, Vecchiet, J., additional, Iapadre, N., additional, Barlattani, A., additional, Bertoli, A., additional, Mari, T., additional, Pasquazzi, C., additional, Missale, G., additional, Sarrecchia, C., additional, Orecchini, E., additional, Michienzi, A., additional, Andreoni, M., additional, Francioso, S., additional, Angelico, M., additional, Ceccherini-Silberstein, F., additional, Locarnini, S., additional, Perno, C.-F., additional, and Svicher, V., additional
- Published
- 2015
- Full Text
- View/download PDF
8. Preparation and characterization of novel proton conducting membranes for thin film fuel cell
- Author
-
BOCCHETTA, Patrizia, DI QUARTO, Francesco, F. CONCIAURO, G. CHIAVAROTTI, Naim. H. Afgan, F. Orecchini e A. Santiangeli, Bocchetta, Patrizia, Conciauro, Francesca, G., Chiavarotti, F., Di Quarto, BOCCHETTA P, F CONCIAURO, G CHIAVAROTTI, and F DI QUARTO
- Abstract
Chitosan (CS) / Phosphotungstic acid (PTA) polyelectrolytes in the shape of thin films and nanowires supported by Anodic Alumina Membranes (AAM) have been fabricated through solution cast and filtration techniques, respectively. Their ability to function in a H2/O2 fuel cell under mild conditions (room temperature, low humidity and low Pt loading) is proved for the first time. The fabricated membrane electrode assemblies produce power peaks of ∼20 mW cm-2 for both films and nanowires. The CS/PTA films (20-40 μm thick) are able to produce a quite constant power density of ∼10 mW cm-2 recorded for at least 7 h. The gradual decrease of the power output with time observed for CS/PTA nanowires in AAM supports (50 μm thick) is accompanied by a durability of about 6 h, which represents an improvement with respect to previous results obtained in AAM-based fuel cell.
- Published
- 2005
9. N-Acetyl-L-Cysteine (NAC) Blunts Axitinib-Related Adverse Effects in Preclinical Models of Glioblastoma.
- Author
-
Formato A, Salbini M, Orecchini E, Pellegrini M, Buccarelli M, Vitiani LR, Giannetti S, Pallini R, D'Alessandris QG, Lauretti L, Martini M, De Falco V, Levi A, Falchetti ML, and Mongiardi MP
- Subjects
- Animals, Humans, Mice, Reactive Oxygen Species metabolism, Cell Line, Tumor, Disease Models, Animal, Protein Kinase Inhibitors pharmacology, Protein Kinase Inhibitors adverse effects, Protein Kinase Inhibitors therapeutic use, Cellular Senescence drug effects, Axitinib pharmacology, Axitinib therapeutic use, Glioblastoma drug therapy, Glioblastoma pathology, Glioblastoma metabolism, Acetylcysteine pharmacology, Acetylcysteine therapeutic use, Xenograft Model Antitumor Assays, Brain Neoplasms drug therapy, Brain Neoplasms pathology, Brain Neoplasms metabolism
- Abstract
Objective: Axitinib is a tyrosine kinase inhibitor characterized by a strong affinity for Vascular Endothelial Growth Factor Receptors (VEGFRs). It was approved in 2012 by Food and Drug Administration and European Medicines Agency as a second line treatment for advanced renal cell carcinoma and is currently under evaluation in clinical trial for the treatment of other cancers. Glioblastoma IDH-wild type (GBM) is a highly malignant brain tumor characterized by diffusely infiltrative growth pattern and by a prominent neo-angiogenesis. In GBM, axitinib has demonstrated a limited effectiveness as a monotherapy, while it was recently shown to significantly improve its efficacy in combination treatments. In preclinical models, axitinib has been reported to trigger cellular senescence both in tumor as well as in normal cells, through a mechanism involving intracellular reactive oxygen species (ROS) accumulation and activation of Ataxia Telangiectasia Mutated kinase (ATM). Limiting axitinib-dependent ROS increase by antioxidants prevents senescence specifically in normal cells, without affecting tumor cells., Methods: We used brain tumor xenografts obtained by engrafting Glioma Stem Cells (GSCs) into the brain of immunocompromised mice, to investigate the hypothesis that the antioxidant molecule N-Acetyl-L-Cysteine (NAC) might be used to reduce senescence-associated adverse effects of axitinib treatment without altering its anti-tumor activity., Results: We demonstrate that the use of the antioxidant molecule N-Acetyl-Cysteine (NAC) in combination with axitinib stabilizes tumor microvessels in GBM tumor orthotopic xenografts, eventually resulting in vessel normalization, and protects liver vasculature from axitinib-dependent toxicity., Conclusion: Overall, we found that NAC co-treatment allows vessel normalization in brain tumor vessels and exerts a protective effect on liver vasculature, therefore minimizing axitinib-dependent toxicity., (© 2024 The Author(s). Cancer Medicine published by John Wiley & Sons Ltd.)
- Published
- 2024
- Full Text
- View/download PDF
10. Characterization of the molecular dysfunctions occurring in Aicardi-Goutières syndrome patients with mutations in ADAR1.
- Author
-
Al Wardat S, Frassinelli L, Orecchini E, Rey F, Ciafrè SA, Galardi S, Garau J, Gagliardi S, Orcesi S, Tonduti D, Carelli S, Cereda C, Picardi E, and Michienzi A
- Published
- 2023
- Full Text
- View/download PDF
11. Modulation of Indoleamine 2,3-Dioxygenase 1 During Inflammatory Bowel Disease Activity in Humans and Mice.
- Author
-
Proietti E, Pauwels RWM, de Vries AC, Orecchini E, Volpi C, Orabona C, Peppelenbosch MP, Fuhler GM, and Mondanelli G
- Abstract
Background and Aims: Indoleamine 2,3 dioxygenase-1 (IDO1), a key enzyme in tryptophan metabolism, is strongly up-regulated both in human inflammatory bowel disease (IBD) and animal models of colitis, however its role in the pathogenesis is still controversial. In this study, we investigated IDO1 expression and activity in a mouse model of DSS-induced chronic colitis as well as in colon biopsies and sera from IBD patients., Methods: Chronic colitis was induced in mice through the oral administration of dextran sodium sulfate (DSS), and IDO1 activity was induced by i.p. treatment with N-acetyl serotonin (NAS). IDO1 expression and catalytic activity (measured as Kyn/Trp ratio) was evaluated in sera and tissue samples collected from mice and 93 IBD patients under immunotherapy with Vedolizumab (VDZ) or Ustekinumab (UST)., Results: Strong up-regulation of IDO1 was found in colons of mice with acute colitis, which follows disease activity. Enhanced IDO1 activity by NAS treatment protects the intestinal mucosa during the recovery phase of chronic colitis. In IBD patients, IDO1 expression and activity correlate with the severity of mucosal inflammation with inflamed regions showing higher IDO1 expression compared to non-inflamed regions within the same patient. Endoscopic response to VDZ/UST treatment is associated with decreased expression of IDO1., Conclusions: This is the first study demonstrating immunomodulatory activity of IDO1 in a chronic mouse model of DSS-induced colitis. As its expression and catalytic activity correlate with the grade of mucosal inflammation and treatment response, IDO1 could represent a promising biomarker for disease severity and treatment monitoring in IBD., Competing Interests: The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article., (© The Author(s) 2023.)
- Published
- 2023
- Full Text
- View/download PDF
12. The circadian control of tryptophan metabolism regulates the host response to pulmonary fungal infections.
- Author
-
Stincardini C, Pariano M, D'Onofrio F, Renga G, Orecchini E, Orabona C, Nunzi E, Gargaro M, Fallarino F, Chun SK, Fortin BM, Masri S, Brancorsini S, Romani L, Costantini C, and Bellet MM
- Abstract
The environmental light/dark cycle has left its mark on the body's physiological functions to condition not only our inner biology, but also the interaction with external cues. In this scenario, the circadian regulation of the immune response has emerged as a critical factor in defining the host-pathogen interaction and the identification of the underlying circuitry represents a prerequisite for the development of circadian-based therapeutic strategies. The possibility to track down the circadian regulation of the immune response to a metabolic pathway would represent a unique opportunity in this direction. Herein, we show that the metabolism of the essential amino acid tryptophan, involved in the regulation of fundamental processes in mammals, is regulated in a circadian manner in both murine and human cells and in mouse tissues. By resorting to a murine model of pulmonary infection with the opportunistic fungus Aspergillus fumigatus , we showed that the circadian oscillation in the lung of the tryptophan-degrading enzyme indoleamine 2,3-dioxygenase (IDO)1, generating the immunoregulatory kynurenine, resulted in diurnal changes in the immune response and the outcome of fungal infection. In addition, the circadian regulation of IDO1 drives such diurnal changes in a pre-clinical model of cystic fibrosis (CF), an autosomal recessive disease characterized by progressive lung function decline and recurrent infections, thus acquiring considerable clinical relevance. Our results demonstrate that the circadian rhythm at the intersection between metabolism and immune response underlies the diurnal changes in host-fungal interaction, thus paving the way for a circadian-based antimicrobial therapy., (© The Author(s) 2023. Published by Oxford University Press on behalf of National Academy of Sciences.)
- Published
- 2023
- Full Text
- View/download PDF
13. SLC6A4 DNA Methylation Levels and Serum Kynurenine/Tryptophan Ratio in Eating Disorders: A Possible Link with Psychopathological Traits?
- Author
-
Franzago M, Orecchini E, Porreca A, Mondanelli G, Orabona C, Dalla Ragione L, Di Nicola M, Stuppia L, Vitacolonna E, Beccari T, and Ceccarini MR
- Subjects
- Humans, Tryptophan, Kynurenine, DNA Methylation, Serotonin Plasma Membrane Transport Proteins, Feeding and Eating Disorders genetics, Bulimia Nervosa epidemiology, Binge-Eating Disorder psychology, Anorexia Nervosa psychology
- Abstract
Background: The incidence of eating disorders (EDs), serious mental and physical conditions characterized by a disturbance in eating or eating-related behaviors, has increased steadily. The present study aims to develop insights into the pathophysiology of EDs, spanning over biochemical, epigenetic, psychopathological, and clinical data. In particular, we focused our attention on the relationship between (i) DNA methylation profiles at promoter-associated CpG sites of the SCL6A4 gene, (ii) serum kynurenine/tryptophan levels and ratio (Kyn/Trp), and (iii) psychopathological traits in a cohort of ED patients. Among these, 45 patients were affected by restricting anorexia nervosa (AN0), 21 by purging AN (AN1), 21 by bulimia (BN), 31 by binge eating disorders (BED), 23 by unspecified feeding or eating disorders (UFED), and finally 14 by other specified eating disorders (OSFED) were compared to 34 healthy controls (CTRs). Results: Kyn level was higher in BED, UFED, and OSFED compared to CTRs (p ≤ 0.001). On the other hand, AN0, AN1, and BN patients showed significatively lower Kyn levels compared to the other three ED groups but were closed to CTRs. Trp was significantly higher in AN0, AN1, and BN in comparison to other ED groups. Moreover, AN1 and BN showed more relevant Trp levels than CTRs (p <0.001). BED patients showed a lower Trp as compared with CTRs (p ≤ 0.001). In addition, Kyn/Trp ratio was lower in the AN1 subtype but higher in BED, UFED, and OSFED patients than in CTRs (p ≤ 0.001). SCL6A4 DNA methylation level at CpG5 was lower in AN0 compared to BED (p = 0.021), and the CpG6 methylation was also significantly lower in AN0 in comparison to CTRs (p = 0.025). The mean methylation levels of the six CpGs analyzed were lower only in the AN0 subgroup compared to CTRs (p = 0.008). Relevant psychological trait EDI-3 subscales were correlated with biochemical and epigenetic data. Conclusions: These findings underline the complexity of psychological and pathophysiological components of EDs.
- Published
- 2023
- Full Text
- View/download PDF
14. Unrevealing the Role of TLRs in the Pathogenesis of Autoimmune Disease by Using Mouse Model of Diabetes.
- Author
-
Panfili E, Orecchini E, and Mondanelli G
- Subjects
- Animals, Mice, Disease Models, Animal, Toll-Like Receptors, Diabetes Mellitus, Type 1, Autoimmune Diseases
- Abstract
Toll-like receptors (TLRs) are receptors of the innate immune system specialized in recognizing conserved molecular pattern of pathogens and initiating an appropriate immune response. Along with the recognition of foreign materials, TLRs have also been shown to respond to endogenous molecules, thus mediating the development of autoimmune diseases. Type 1 diabetes (T1D) is a prototypic autoimmune disease in which TLRs play a pathogenic role. We here describe a protocol to study the role of TLRs in the development and progression of T1D by resorting to the nonobese diabetic (NOD) mouse model., (© 2023. The Author(s), under exclusive license to Springer Science+Business Media, LLC, part of Springer Nature.)
- Published
- 2023
- Full Text
- View/download PDF
15. Characterization of Glioblastoma Cells Response to Regorafenib.
- Author
-
Mongiardi MP, Buccarelli M, Formato A, Orecchini E, Salbini M, Ricci V, Orsini T, Putti S, Chiesa S, Ricci-Vitiani L, D'Alessandris QG, Pallini R, Levi A, and Falchetti ML
- Abstract
Glioblastoma (GBM), the most malignant primary brain tumor in adults. Although not frequent, it has a relevant social impact because the peak incidence coincides with the age of professional maturity. A number of novel treatments have been proposed, yet clinical trials have been disappointing. Recently, a phase II clinical trial (REGOMA) demonstrated that the multikinase inhibitor regorafenib significantly increased the median overall survival (OS) of GBM patients when compared to lomustine-treated patients. On this basis, the National Comprehensive Cancer Network (NCCN) 2020 Guidelines included regorafenib as a preferred regimen in relapsed GBM treatment. Despite the use in GBM patients' therapy, little is known about the molecular mechanisms governing regorafenib effectiveness on the GBM tumor. Here we report an in vitro characterization of GBM tumor cells' response to regorafenib, performed both on cell lines and on patient-derived glioma stem cells (GSCs). Overall, regorafenib significantly reduced cell growth of 2D tumor cell cultures and of 3D tumor spheroids. Strikingly, this effect was accompanied by transcriptional regulation of epithelial to mesenchymal transition (EMT) genes and by an increased ability of surviving tumor cells to invade the surrounding matrix. Taken together, our data suggest that regorafenib limits cell growth, however, it might induce an invasive phenotype.
- Published
- 2022
- Full Text
- View/download PDF
16. The immunosuppression pathway of tumor-associated macrophages is controlled by heme oxygenase-1 in glioblastoma patients.
- Author
-
Magri S, Musca B, Pinton L, Orecchini E, Belladonna ML, Orabona C, Bonaudo C, Volpin F, Ciccarino P, Baro V, Della Puppa A, and Mandruzzato S
- Subjects
- Humans, B7-H1 Antigen metabolism, Heme, Immunosuppression Therapy, Interleukin-10, Iron, Tumor Microenvironment, Glioblastoma pathology, Heme Oxygenase-1 genetics, Heme Oxygenase-1 metabolism, Tumor-Associated Macrophages
- Abstract
The immunosuppressive tumor microenvironment (TME) in glioblastoma (GBM) is mainly driven by tumor-associated macrophages (TAMs). We explored whether their sustained iron metabolism and immunosuppressive activity were correlated, and whether blocking the central enzyme of the heme catabolism pathway, heme oxygenase-1 (HO-1), could reverse their tolerogenic activity. To this end, we investigated iron metabolism in bone marrow-derived macrophages (BMDMs) isolated from GBM specimens and in in vitro-derived macrophages (Mφ) from healthy donor (HD) blood monocytes. We found that HO-1 inhibition abrogated the immunosuppressive activity of both BMDMs and Mφ, and that immunosuppression requires both cell-to-cell contact and soluble factors, as HO-1 inhibition abolished IL-10 release, and significantly reduced STAT3 activation as well as PD-L1 expression. Interestingly, not only did HO-1 inhibition downregulate IDO1 and ARG-2 gene expression, but also reduced IDO1 enzymatic activity. Moreover, T cell activation status affected PD-L1 expression and IDO1 activity, which were upregulated in the presence of activated, but not resting, T cells. Our results highlight the crucial role of HO-1 in the immunosuppressive activity of macrophages in the GBM TME and demonstrate the feasibility of reprogramming them as an alternative therapeutic strategy for restoring immune surveillance., (© 2022 The Authors. International Journal of Cancer published by John Wiley & Sons Ltd on behalf of UICC.)
- Published
- 2022
- Full Text
- View/download PDF
17. Crocus sativus L. Petal Extract Inhibits Inflammation and Osteoclastogenesis in RAW 264.7 Cell Model.
- Author
-
Orabona C, Orecchini E, Volpi C, Bacaloni F, Panfili E, Pagano C, Perioli L, and Belladonna ML
- Abstract
The dried stigmas of Crocus sativus L. (Iridaceae) are traditionally processed to produce saffron, a spice widely used as a food coloring and flavoring agent, which is important in the pharmaceutical and textile dye-producing industries. The labor-intensive by-hand harvesting and the use of only a small amount of each flower cause saffron to be the most expensive spice in the world. Crocus sp. petals are by-products of saffron production and represent an interesting raw material for the preparation of extracts intended for health protection in the perspective of a circular economy. In the present study, ethanolic extract from Crocus sativus L. petals ( Crocus sativus L. petal extract, Cs PE) was tested on macrophages by in vitro models of inflammation and osteoclastogenesis. The extract was found to be endowed with anti-inflammatory activity, significantly reducing the nitric oxide production and IL-6 release by RAW 264.7 murine cells. Moreover, Cs PE demonstrated an anti-osteoclastogenic effect, as revealed by a complete inhibition of tartrate-resistant acid phosphatase (TRAP)-positive osteoclast formation and a decreased expression of key osteoclast-related genes. This study, which focuses on the macrophage as the target cell of the bioactive extract from Crocus sativus L. petals, suggests that the petal by-product of saffron processing can usefully be part of a circular economy network aimed at producing an extract that potentially prevents bone disruption.
- Published
- 2022
- Full Text
- View/download PDF
18. The [1,2,4]Triazolo[4,3-a]pyridine as a New Player in the Field of IDO1 Catalytic Holo-Inhibitors.
- Author
-
Fallarini S, Bhela IP, Aprile S, Torre E, Ranza A, Orecchini E, Panfili E, Pallotta MT, Massarotti A, Serafini M, and Pirali T
- Subjects
- Humans, Cell Line, Tumor, Cell Survival drug effects, Dose-Response Relationship, Drug, Drug Screening Assays, Antitumor, Molecular Structure, Structure-Activity Relationship, Antineoplastic Agents chemical synthesis, Antineoplastic Agents chemistry, Antineoplastic Agents pharmacology, Enzyme Inhibitors chemical synthesis, Enzyme Inhibitors chemistry, Enzyme Inhibitors pharmacology, Indoleamine-Pyrrole 2,3,-Dioxygenase antagonists & inhibitors, Indoleamine-Pyrrole 2,3,-Dioxygenase metabolism
- Abstract
Inhibitors of indoleamine 2,3-dioxygenase 1 (IDO1) are considered a promising strategy in cancer immunotherapy as they are able to boost the immune response and to work in synergy with other immunotherapeutic agents. Despite the fact that no IDO1 inhibitor has been approved so far, recent studies have shed light on the additional roles that IDO1 mediates beyond its catalytic activity, conferring new life to the field. Here we present a novel class of compounds originated from a structure-based virtual screening made on IDO1 active site. The starting hit compound is a novel chemotype based on a [1,2,4]triazolo[4,3-a]pyridine scaffold, so far underexploited among the heme binding moieties. Thanks to the rational and in silico-guided design of analogues, an improvement of the potency to sub-micromolar levels has been achieved, with excellent in vitro metabolic stability and exquisite selectivity with respect to other heme-containing enzymes., (© 2021 The Authors. ChemMedChem published by Wiley-VCH GmbH.)
- Published
- 2021
- Full Text
- View/download PDF
19. The RNA editing enzyme ADAR2 restricts L1 mobility.
- Author
-
Frassinelli L, Orecchini E, Al-Wardat S, Tripodi M, Mancone C, Doria M, Galardi S, Ciafrè SA, and Michienzi A
- Subjects
- Adenosine Deaminase genetics, HEK293 Cells, HeLa Cells, Humans, RNA-Binding Proteins genetics, Adenosine Deaminase metabolism, Long Interspersed Nucleotide Elements, RNA Editing, RNA-Binding Proteins metabolism
- Abstract
Adenosine deaminases acting on RNA (ADARs) are enzymes that convert adenosines to inosines in double-stranded RNAs (RNA editing A-to-I). ADAR1 and ADAR2 were previously reported as HIV-1 proviral factors. The aim of this study was to investigate the composition of the ADAR2 ribonucleoprotein complex during HIV-1 expression. By using a dual-tag affinity purification procedure in cells expressing HIV-1 followed by mass spectrometry analysis, we identified 10 non-ribosomal ADAR2-interacting factors. A significant fraction of these proteins was previously found associated to the Long INterspersed Element 1 (LINE1 or L1) ribonucleoparticles and to regulate the life cycle of L1 retrotransposons. Considering that we previously demonstrated that ADAR1 is an inhibitor of LINE-1 retrotransposon activity, we investigated whether also ADAR2 played a similar function. To reach this goal, we performed specific cell culture retrotransposition assays in cells overexpressing or ablated for ADAR2. These experiments unveil a novel function of ADAR2 as suppressor of L1 retrotransposition. Furthermore, we showed that ADAR2 binds the basal L1 RNP complex.Overall, these data support the role of ADAR2 as regulator of L1 life cycle.
- Published
- 2021
- Full Text
- View/download PDF
20. Pathogenetic Interplay Between IL-6 and Tryptophan Metabolism in an Experimental Model of Obesity.
- Author
-
Mondanelli G, Albini E, Orecchini E, Pallotta MT, Belladonna ML, Ricci G, Grohmann U, and Orabona C
- Subjects
- Adipose Tissue metabolism, Animals, Biomarkers, Cytokines metabolism, Diet, High-Fat, Disease Models, Animal, Hepatocytes metabolism, Indoleamine-Pyrrole 2,3,-Dioxygenase metabolism, Insulin metabolism, Kynurenine metabolism, Male, Mice, Obesity pathology, Receptors, Interleukin-6 metabolism, Disease Susceptibility, Energy Metabolism, Interleukin-6 metabolism, Obesity etiology, Obesity metabolism, Tryptophan metabolism
- Abstract
Obesity is a metabolic disease characterized by a state of chronic, low-grade inflammation and dominated by pro-inflammatory cytokines such as IL-6. Indoleamine 2,3-dioxygenase 1 (IDO1) is an enzyme that catalyzes the first step in the kynurenine pathway by transforming l-tryptophan (Trp) into l-kynurenine (Kyn), a metabolite endowed with anti-inflammatory and immunoregulatory effects. In dendritic cells, IL-6 induces IDO1 proteasomal degradation and shuts down IDO1-mediated immunosuppressive effects. In tumor cells, IL-6 upregulates IDO1 expression and favors tumor immune escape mechanisms. To investigate the role of IDO1 and its possible relationship with IL-6 in obesity, we induced the disease by feeding mice with a high fat diet (HFD). Mice on a standard diet were used as control. Experimental obesity was associated with high IDO1 expression and Kyn levels in the stromal vascular fraction of visceral white adipose tissue (SVF WAT). IDO1-deficient mice on HFD gained less weight and were less insulin resistant as compared to wild type counterparts. Administration of tocilizumab (TCZ), an IL-6 receptor (IL-6R) antagonist, to mice on HFD significantly reduced weight gain, controlled adipose tissue hypertrophy, increased insulin sensitivity, and induced a better glucose tolerance. TCZ also induced a dramatic inhibition of IDO1 expression and Kyn production in the SVF WAT. Thus our data indicated that the IL-6/IDO1 axis may play a pathogenetic role in a chronic, low-grade inflammation condition, and, perhaps most importantly, IL-6R blockade may be considered a valid option for obesity treatment., Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2021 Mondanelli, Albini, Orecchini, Pallotta, Belladonna, Ricci, Grohmann and Orabona.)
- Published
- 2021
- Full Text
- View/download PDF
21. Emulgel Loaded with Flaxseed Extracts as New Therapeutic Approach in Wound Treatment.
- Author
-
Pagano C, Baiocchi C, Beccari T, Blasi F, Cossignani L, Ceccarini MR, Orabona C, Orecchini E, Di Raimo E, Primavilla S, Salvini L, Michele AD, Perioli L, and Ricci M
- Abstract
Dry (D.E.) and liquid (L.E.) extracts were prepared from flaxseeds and their application in health field was evaluated. The chemical analysis showed that D.E. is rich in the lignan secoisolariciresinol diglucoside and L.E. in unsaturated triglycerides containing linolenic acid. Mainly, D.E. showed reducing (15.73 μmol Fe
2+ /g) and radical scavenging capacities (5.25 mg TE/g) and ability to down-regulate the expression of the pro-inflammatory cytokines NO (IC50 = 0.136 ± 0.009 mg/mL) and IL-6 (IC50 = 0.308 ± 0.103 mg/mL), suggesting its use in wound treatment. D.E. and L.E. were active against S. pyogenes and D.E. also against S. aureus . The two extracts were combined in a novel O/W emulgel in which the water phase was viscosized using a low molecular weight and highly deacetylated chitosan (1% wt./v). The presence of this polymer in the emulgel decreased the MIC values of the extracts. In fact, MIC shifted from 0.59 mg/mL to 0.052 mg/mL for D.E. and from 0.22 mg/mL to 0.036 mg/mL for L.E., concentrations safe both for keratinocytes and macrophages. Moreover, the emulgel demonstrated to inhibit S. aureus , P. aeruginosa , S. pyogenes , E. coli, and K. pneumoniae growth (inhibition halos 24-36 mm), strains often responsible for diabetic foot ulcer infection.- Published
- 2021
- Full Text
- View/download PDF
22. Epitranscriptomics: A New Layer of microRNA Regulation in Cancer.
- Author
-
De Paolis V, Lorefice E, Orecchini E, Carissimi C, Laudadio I, and Fulci V
- Abstract
MicroRNAs are pervasive regulators of gene expression at the post-transcriptional level in metazoan, playing key roles in several physiological and pathological processes. Accordingly, these small non-coding RNAs are also involved in cancer development and progression. Furthermore, miRNAs represent valuable diagnostic and prognostic biomarkers in malignancies. In the last twenty years, the role of RNA modifications in fine-tuning gene expressions at several levels has been unraveled. All RNA species may undergo post-transcriptional modifications, collectively referred to as epitranscriptomic modifications, which, in many instances, affect RNA molecule properties. miRNAs are not an exception, in this respect, and they have been shown to undergo several post-transcriptional modifications. In this review, we will summarize the recent findings concerning miRNA epitranscriptomic modifications, focusing on their potential role in cancer development and progression.
- Published
- 2021
- Full Text
- View/download PDF
23. Human Indoleamine 2,3-dioxygenase 1 (IDO1) Expressed in Plant Cells Induces Kynurenine Production.
- Author
-
Bellucci M, Pompa A, De Marcos Lousa C, Panfili E, Orecchini E, Maricchiolo E, Fraternale D, Orabona C, De Marchis F, and Pallotta MT
- Subjects
- Agrobacterium tumefaciens genetics, Cloning, Molecular, Green Fluorescent Proteins metabolism, Humans, Indoleamine-Pyrrole 2,3,-Dioxygenase metabolism, Plasmids genetics, Protein Stability, Recombinant Proteins chemistry, Recombinant Proteins metabolism, Nicotiana genetics, Nicotiana metabolism, Transformation, Bacterial, Agrobacterium tumefaciens physiology, Green Fluorescent Proteins genetics, Indoleamine-Pyrrole 2,3,-Dioxygenase genetics, Kynurenine metabolism, Nicotiana microbiology
- Abstract
Genetic engineering of plants has turned out to be an attractive approach to produce various secondary metabolites. Here, we attempted to produce kynurenine, a health-promoting metabolite, in plants of Nicotiana tabacum (tobacco) transformed by Agrobacterium tumefaciens with the gene, coding for human indoleamine 2,3-dioxygenase 1 (IDO1), an enzyme responsible for the kynurenine production because of tryptophan degradation. The presence of IDO1 gene in transgenic plants was confirmed by PCR, but the protein failed to be detected. To confer higher stability to the heterologous human IDO1 protein and to provide a more sensitive method to detect the protein of interest, we cloned a gene construct coding for IDO1-GFP. Analysis of transiently transfected tobacco protoplasts demonstrated that the IDO1-GFP gene led to the expression of a detectable protein and to the production of kynurenine in the protoplast medium. Interestingly, the intracellular localisation of human IDO1 in plant cells is similar to that found in mammal cells, mainly in cytosol, but in early endosomes as well. To the best of our knowledge, this is the first report on the expression of human IDO1 enzyme capable of secreting kynurenines in plant cells.
- Published
- 2021
- Full Text
- View/download PDF
24. Novel mutations in the WFS1 gene are associated with Wolfram syndrome and systemic inflammation.
- Author
-
Panfili E, Mondanelli G, Orabona C, Belladonna ML, Gargaro M, Fallarino F, Orecchini E, Prontera P, Proietti E, Frontino G, Tirelli E, Iacono A, Vacca C, Puccetti P, Grohmann U, Esposito S, and Pallotta MT
- Subjects
- Child, Cytokines genetics, Cytokines metabolism, Female, Gene Expression Regulation, Humans, Leukocytes, Mononuclear immunology, Sequence Analysis, DNA, Wolfram Syndrome genetics, Wolfram Syndrome immunology, Wolfram Syndrome physiopathology, Inflammation, Leukocytes, Mononuclear metabolism, Membrane Proteins genetics, Mutation, Wolfram Syndrome metabolism
- Abstract
Mutations in the WFS1 gene, encoding wolframin (WFS1), cause endoplasmic reticulum (ER) stress and are associated with a rare autosomal-recessive disorder known as Wolfram syndrome (WS). WS is clinically characterized by childhood-onset diabetes mellitus, optic atrophy, deafness, diabetes insipidus and neurological signs. We identified two novel WFS1 mutations in a patient with WS, namely, c.316-1G > A (in intron 3) and c.757A > T (in exon 7). Both mutations, located in the N-terminal region of the protein, were predicted to generate a truncated and inactive form of WFS1. We found that although the WFS1 protein was not expressed in peripheral blood mononuclear cells (PBMCs) of the proband, no constitutive ER stress activation could be detected in those cells. In contrast, WS proband's PBMCs produced very high levels of proinflammatory cytokines (i.e. TNF-α, IL-1β, and IL-6) in the absence of any stimulus. WFS1 silencing in PBMCs from control subjects by means of small RNA interference also induced a pronounced proinflammatory cytokine profile. The same cytokines were also significantly higher in sera from the WS patient as compared to matched healthy controls. Moreover, the chronic inflammatory state was associated with a dominance of proinflammatory T helper 17 (Th17)-type cells over regulatory T (Treg) lymphocytes in the WS PBMCs. The identification of a state of systemic chronic inflammation associated with WFS1 deficiency may pave the way to innovative and personalized therapeutic interventions in WS., (© The Author(s) 2021. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oup.com.)
- Published
- 2021
- Full Text
- View/download PDF
25. Kynurenine/Tryptophan Ratio as a Potential Blood-Based Biomarker in Non-Small Cell Lung Cancer.
- Author
-
Mandarano M, Orecchini E, Bellezza G, Vannucci J, Ludovini V, Baglivo S, Tofanetti FR, Chiari R, Loreti E, Puma F, Sidoni A, and Belladonna ML
- Subjects
- Adenocarcinoma of Lung blood, Adenocarcinoma of Lung pathology, Adenocarcinoma of Lung surgery, Adult, Aged, Aged, 80 and over, B7-H1 Antigen metabolism, Carcinoma, Non-Small-Cell Lung blood, Carcinoma, Non-Small-Cell Lung surgery, Carcinoma, Squamous Cell blood, Carcinoma, Squamous Cell pathology, Carcinoma, Squamous Cell surgery, Female, Follow-Up Studies, Humans, Indoleamine-Pyrrole 2,3,-Dioxygenase metabolism, Lung Neoplasms blood, Lung Neoplasms surgery, Lymphocytes, Tumor-Infiltrating immunology, Male, Middle Aged, Neoplasm Recurrence, Local blood, Neoplasm Recurrence, Local pathology, Neoplasm Recurrence, Local surgery, Prognosis, Survival Rate, Biomarkers, Tumor blood, Carcinoma, Non-Small-Cell Lung pathology, Kynurenine blood, Lung Neoplasms pathology, Tryptophan blood
- Abstract
The enzyme indoleamine 2,3-dioxygenase 1 (IDO1) degrade tryptophan (Trp) into kynurenine (Kyn) at the initial step of an enzymatic pathway affecting T cell proliferation. IDO1 is highly expressed in various cancer types and associated with poor prognosis. Nevertheless, the serum Kyn/Trp concentration ratio has been suggested as a marker of cancer-associated immune suppression. We measured Kyn and Trp in blood samples of a wide cohort of non-small-cell lung cancer (NSCLC) patients, before they underwent surgery, and analyzed possible correlations of the Kyn/Trp ratio with either IDO1 expression or clinical-pathological parameters. Low Kyn/Trp significantly correlated with low IDO1 expression and never-smoker patients; while high Kyn/Trp was significantly associated with older (≥68 years) patients, advanced tumor stage, and squamous cell carcinoma (Sqcc), rather than the adenocarcinoma (Adc) histotype. Moreover, high Kyn/Trp was associated, among the Adc group, with higher tumor stages (II and III), and, among the Sqcc group, with a high density of tumor-infiltrating lymphocytes. A trend correlating the high Kyn/Trp ratio with the probability of recurrences from NSCLC was also found. In conclusion, high serum Kyn/Trp ratio, associated with clinical and histopathological parameters, may serve as a serum biomarker to optimize risk stratification and therapy of NSCLC patients.
- Published
- 2021
- Full Text
- View/download PDF
26. Artocarpus tonkinensis Extract Inhibits LPS-Triggered Inflammation Markers and Suppresses RANKL-Induced Osteoclastogenesis in RAW264.7.
- Author
-
Orecchini E, Mondanelli G, Orabona C, Volpi C, Adorisio S, Calvitti M, Thuy TT, Delfino DV, and Belladonna ML
- Abstract
Artocarpus tonkinensis ( At ) leaf decoction, a traditional remedy prepared in North Vietnam by the Hmong ethnic group, is a tea extract rich in bioactive compounds that may have therapeutic effects in arthritis and backache. Indeed, it has been demonstrated that At is able to inhibit Th17 lymphocytes development and to protect mice in an experimental model of collagen-induced arthritis. By resorting to macrophage in vitro models of inflammation and osteoclastogenesis, we showed that At extract significantly reduced nitric oxide synthase 2 (NOS2) activity and IL-6 production by RAW 264.7 murine cells. Moreover, At demonstrated an anti-osteoclastogenic effect, as revealed by complete inhibition of TRAP-positive osteoclast formation and decreased expression of key osteoclast-related genes. This At activity likely relies on the inhibition of RANK downstream signaling pathway, as the activation of non-receptor tyrosine kinase Src is reduced upon RANKL- At exposure. Protective effect of At against bone loss was also enlightened in vivo by collagen-induced arthritis (CIA) experiment demonstrating that, although paw edema was only weakly opposed by drinking At decoction, bone and cartilage were well preserved in CIA+ At mice and joint tissue expressed decreased levels of osteoclast marker genes respect to CIA control group. Maesopsin 4-O-β-D-glucoside (i.e., TAT-2, one of the main decoction bioactive components) was capable to contrast NOS2 activity, IL-6 expression and osteoclast formation, too, albeit to a lesser extent when compared to At decoction. Overall, this study enlightens another At cell target, macrophages, beside Th17 lymphocytes, and suggests that the anti-arthritic beneficial effects of At decoction largely derives from its ability to counteract not only inflammation, but also osteoclastogenesis., Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2021 Belladonna, Orecchini, Mondanelli, Orabona, Volpi, Adorisio, Thuy and Delfino.)
- Published
- 2021
- Full Text
- View/download PDF
27. Effect of Probiotic Administration on Serum Tryptophan Metabolites in Pediatric Type 1 Diabetes Patients.
- Author
-
Mondanelli G, Orecchini E, Volpi C, Panfili E, Belladonna ML, Pallotta MT, Moretti S, Galarini R, Esposito S, and Orabona C
- Abstract
Type 1 diabetes (T1D) is characterized by anomalous functioning of the immuno regulatory, tryptophan-catabolic enzyme indoleamine 2,3 dioxygenase 1 (IDO1). In T1D, the levels of kynurenine-the first byproduct of tryptophan degradation via IDO1-are significantly lower than in nondiabetic controls, such that defective immune regulation by IDO1 has been recognized as potentially contributing to autoimmunity in T1D. Because tryptophan catabolism-and the production of immune regulatory catabolites-also occurs via the gut microbiota, we measured serum levels of tryptophan, and metabolites thereof, in pediatric, diabetic patients after a 3-month oral course of Lactobacillus rhamnosus GG. Daily administration of the probiotic significantly affected circulating levels of tryptophan as well as the qualitative pattern of metabolite formation in the diabetic patients, while it decreased inflammatory cytokine production by the patients. This study suggests for the first time that a probiotic treatment may affect systemic tryptophan metabolism and restrain proinflammatory profile in pediatric T1D., Competing Interests: Declaration of Conflicting Interests:The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article., (© The Author(s) 2020.)
- Published
- 2020
- Full Text
- View/download PDF
28. Discovery of Highly Potent Benzimidazole Derivatives as Indoleamine 2,3-Dioxygenase-1 (IDO1) Inhibitors: From Structure-Based Virtual Screening to in Vivo Pharmacodynamic Activity.
- Author
-
Serafini M, Torre E, Aprile S, Grosso ED, Gesù A, Griglio A, Colombo G, Travelli C, Paiella S, Adamo A, Orecchini E, Coletti A, Pallotta MT, Ugel S, Massarotti A, Pirali T, and Fallarini S
- Subjects
- Animals, Benzimidazoles blood, Cell Line, Tumor, Cells, Cultured, Enzyme Inhibitors blood, Humans, Indoleamine-Pyrrole 2,3,-Dioxygenase chemistry, Indoleamine-Pyrrole 2,3,-Dioxygenase metabolism, Male, Mice, Molecular Docking Simulation, Structure-Activity Relationship, Benzimidazoles chemistry, Benzimidazoles pharmacology, Enzyme Inhibitors chemistry, Enzyme Inhibitors pharmacology, Indoleamine-Pyrrole 2,3,-Dioxygenase antagonists & inhibitors
- Abstract
In this study, a successful medicinal chemistry campaign that exploited virtual, biophysical, and biological investigations led to the identification of a novel class of IDO1 inhibitors based on a benzimidazole substructure. This family of compounds is endowed with an extensive bonding network in the protein active site, including the interaction with pocket C, a region not commonly exploited by previously reported IDO1 inhibitors. The tight packing of selected compounds within the enzyme contributes to the strong binding interaction with IDO1, to the inhibitory potency at the low nanomolar level in several tumoral settings, and to the selectivity toward IDO1 over TDO and CYPs. Notably, a significant reduction of L-Kyn levels in plasma, together with a potent effect on abrogating immunosuppressive properties of MDSC-like cells isolated from patients affected by pancreatic ductal adenocarcinoma, was observed, pointing to this class of molecules as a valuable template for boosting the antitumor immune system.
- Published
- 2020
- Full Text
- View/download PDF
29. Bioadhesive Polymeric Films Based on Red Onion Skins Extract for Wound Treatment: An Innovative and Eco-Friendly Formulation.
- Author
-
Pagano C, Marinozzi M, Baiocchi C, Beccari T, Calarco P, Ceccarini MR, Chielli M, Orabona C, Orecchini E, Ortenzi R, Ricci M, Scuota S, Tiralti MC, and Perioli L
- Subjects
- Animals, Mice, RAW 264.7 Cells, Swine, Anti-Bacterial Agents chemistry, Anti-Bacterial Agents pharmacology, Anti-Inflammatory Agents chemistry, Anti-Inflammatory Agents pharmacology, Membranes, Artificial, Onions chemistry, Plant Extracts chemistry, Plant Extracts pharmacology, Skin injuries, Skin metabolism, Skin microbiology, Tissue Adhesives chemistry, Tissue Adhesives pharmacology, Wound Healing drug effects
- Abstract
The onion non-edible outside layers represent a widely available waste material deriving from its processing and consumption. As onion is a vegetable showing many beneficial properties for human health, a study aiming to evaluate the use of extract deriving from the non-edible outside layers was planned. An eco-friendly extraction method was optimized using a hydroalcoholic solution as solvent. The obtained extract was deeply characterized by in vitro methods and then formulated in autoadhesive, biocompatible and pain-free hydrogel polymeric films. The extract, very soluble in water, showed antioxidant, radical scavenging, antibacterial and anti-inflammatory activities, suggesting a potential dermal application for wounds treatment. In vitro studies showed a sustained release of the extract from the hydrogel polymeric film suitable to reach concentrations necessary for both antibacterial and anti-inflammatory activities. Test performed on human keratinocytes showed that the formulation is safe suggesting that the projected formulation could be a valuable tool for wound treatment.
- Published
- 2020
- Full Text
- View/download PDF
30. Post-transcriptional regulation of LINE-1 retrotransposition by AID/APOBEC and ADAR deaminases.
- Author
-
Orecchini E, Frassinelli L, Galardi S, Ciafrè SA, and Michienzi A
- Subjects
- DNA metabolism, Humans, RNA metabolism, RNA, Double-Stranded metabolism, APOBEC Deaminases metabolism, Adenosine Deaminase metabolism, Cytidine Deaminase metabolism, Long Interspersed Nucleotide Elements, Retroelements
- Abstract
Long interspersed element-1 (LINE-1 or L1) retrotransposons represent the only functional family of autonomous transposable elements in humans and formed 17% of our genome. Even though most of the human L1 sequences are inactive, a limited number of copies per individual retain the ability to mobilize by a process termed retrotransposition. The ongoing L1 retrotransposition may result in insertional mutagenesis that could lead to negative consequences such as genetic disease and cancer. For this reason, cells have evolved several mechanisms of defense to restrict L1 activity. Among them, a critical role for cellular deaminases [activation-induced deaminase (AID)/apolipoprotein B mRNA-editing catalytic polypeptide-like (APOBEC) and adenosine deaminases that act on RNA (ADAR) enzymes] has emerged. The majority of the AID/APOBEC family of proteins are responsible for the deamination of cytosine to uracil (C-to-U editing) within DNA and RNA targets. The ADARs convert adenosine bases to inosines (A-to-I editing) within double-stranded RNA (dsRNA) targets. This review will discuss the current understanding of the regulation of LINE-1 retrotransposition mediated by these enzymes.
- Published
- 2018
- Full Text
- View/download PDF
31. Restricting retrotransposons: ADAR1 is another guardian of the human genome.
- Author
-
Orecchini E, Frassinelli L, and Michienzi A
- Subjects
- Adenosine metabolism, Adenosine Deaminase metabolism, Autoimmune Diseases of the Nervous System genetics, Autoimmune Diseases of the Nervous System metabolism, Autoimmune Diseases of the Nervous System pathology, Biological Assay, HeLa Cells, Humans, Inosine metabolism, Nervous System Malformations genetics, Nervous System Malformations metabolism, Nervous System Malformations pathology, RNA metabolism, RNA, Small Interfering genetics, RNA, Small Interfering metabolism, RNA-Binding Proteins antagonists & inhibitors, RNA-Binding Proteins metabolism, Ribonucleoproteins genetics, Ribonucleoproteins metabolism, Adenosine Deaminase genetics, Genome, Human, Long Interspersed Nucleotide Elements, RNA genetics, RNA Editing, RNA-Binding Proteins genetics
- Abstract
ADAR1 is an enzyme that belongs to the Adenosine Deaminases Acting on RNA (ADARs) family. These enzymes deaminate adenosines to inosines (RNA editing A-to-I) within double-stranded RNA regions in transcripts. Since inosines are recognized as guanosines by the cellular machinery, RNA editing mediated by ADARs can either lead to the formation of an altered protein (recoding) or affect different aspects of RNA metabolism. Recently, a proteomic analysis led to the identification of novel ADAR1-associated factors and found that a good fraction of them is shared with the Long Interspersed Element 1 (LINE-1 or L1) ribonucleoparticles (RNPs). This evidence suggested a possible role of ADAR1 in regulating the L1 life cycle. By taking advantage of the use of cell culture retrotransposition assays, a novel function of this deaminase as an inhibitor of L1 retrotransposition was demonstrated. These results pave the way toward a better comprehension of the mechanisms of restriction of retrotransposons.
- Published
- 2017
- Full Text
- View/download PDF
32. Novel HBsAg mutations correlate with hepatocellular carcinoma, hamper HBsAg secretion and promote cell proliferation in vitro.
- Author
-
Salpini R, Surdo M, Warner N, Cortese MF, Colledge D, Soppe S, Bellocchi MC, Armenia D, Carioti L, Continenza F, Di Carlo D, Saccomandi P, Mirabelli C, Pollicita M, Longo R, Romano S, Cappiello G, Spanò A, Trimoulet P, Fleury H, Vecchiet J, Iapadre N, Barlattani A, Bertoli A, Mari T, Pasquazzi C, Missale G, Sarrecchia C, Orecchini E, Michienzi A, Andreoni M, Francioso S, Angelico M, Verheyen J, Ceccherini-Silberstein F, Locarnini S, Perno CF, and Svicher V
- Subjects
- Adult, Aged, Carcinoma, Hepatocellular virology, Cell Cycle, Cell Proliferation, Female, Gene Frequency, Genotype, Hepatitis B Surface Antigens metabolism, Hepatitis B virus metabolism, Hepatitis B virus physiology, Hepatitis B, Chronic virology, Host-Pathogen Interactions, Humans, Liver Neoplasms virology, Male, Middle Aged, Multivariate Analysis, Risk Factors, Carcinoma, Hepatocellular pathology, Hepatitis B Surface Antigens genetics, Hepatitis B virus genetics, Hepatitis B, Chronic pathology, Liver Neoplasms pathology, Mutation
- Abstract
Background: An impaired HBsAg-secretion can increase HBV oncogenic-properties. Here, we investigate genetic-determinants in HBsAg correlated with HBV-induced hepatocellular carcinoma (HCC), and their impact on HBsAg-secretion and cell-proliferation., Methods: This study included 128 chronically HBV-infected patients: 23 with HCC (73.9% D; 26.1% A HBV-genotype), and 105 without cirrhosis/HCC (72.4% D, 27.6% A) as reference-group. The impact of mutations on HBsAg-secretion was assessed by measuring the ratio [secreted/intracellular HBsAg] until day 5 post-transfection. The impact of mutations on cell-cycle advancement was assessed by flow-cytometry., Results: Two HBsAg mutations significantly correlated with HCC: P203Q (17.4% [4/23] in HCC vs 1.0% [1/105] in non-HCC, P=0.004); S210R (34.8% [8/23] in HCC vs 3.8% [4/105] in non-HCC, P <0.001); P203Q+S210R (17.4% [4/23] in HCC vs 0% [0/110] in non-HCC, P=0.001). Both mutations reside in trans-membrane C-terminal domain critical for HBsAg-secretion. In in-vitro experiments, P203Q, S210R and P203Q+S210R significantly reduced the ratio [secreted/intracellular HBsAg] compared to wt at each time-point analysed (P <0.05), supporting an impaired HBsAg-secretion. Furthermore, P203Q and P203Q+S210R increased the percentage of cells in S-phase compared to wt, indicating cell-cycle progression (P203Q:26±13%; P203Q+S210R:29±14%; wt:18%±9, P <0.01. Additionally, S210R increased the percentage of cells in G2/M-phase (26±8% for wt versus 33±6% for S210R, P <0.001)., Conclusions: Specific mutations in HBsAg C-terminus significantly correlate with HBV-induced HCC. They hamper HBsAg-secretion and are associated with increased cellular proliferation, supporting their involvement in HCC-development. The identification of viral genetic markers associated with HCC is critical to identify patients at higher HCC-risk that may deserve intensive liver monitoring, and/or early anti-HBV therapy.
- Published
- 2017
- Full Text
- View/download PDF
33. ADAR1 restricts LINE-1 retrotransposition.
- Author
-
Orecchini E, Doria M, Antonioni A, Galardi S, Ciafrè SA, Frassinelli L, Mancone C, Montaldo C, Tripodi M, and Michienzi A
- Subjects
- Adenosine Deaminase metabolism, Biological Assay, Gene Expression Profiling, Gene Expression Regulation, HEK293 Cells, HIV-1 metabolism, HeLa Cells, Heat-Shock Proteins genetics, Heat-Shock Proteins metabolism, Host-Pathogen Interactions, Humans, Molecular Sequence Annotation, Protein Binding, RNA-Binding Proteins metabolism, Ribonucleoproteins metabolism, Signal Transduction, Adenosine Deaminase genetics, HIV-1 genetics, Long Interspersed Nucleotide Elements, RNA-Binding Proteins genetics, Retroelements, Ribonucleoproteins genetics
- Abstract
Adenosine deaminases acting on RNA (ADARs) are involved in RNA editing that converts adenosines to inosines in double-stranded RNAs. ADAR1 was demonstrated to be functional on different viruses exerting either antiviral or proviral effects. Concerning HIV-1, several studies showed that ADAR1 favors viral replication. The aim of this study was to investigate the composition of the ADAR1 ribonucleoprotein complex during HIV-1 expression. By using a dual-tag affinity purification procedure in cells expressing HIV-1 followed by mass spectrometry analysis, we identified 14 non-ribosomal ADAR1-interacting proteins, most of which are novel. A significant fraction of these proteins were previously demonstrated to be associated to the Long INterspersed Element 1 (LINE1 or L1) ribonucleoparticles and to regulate the life cycle of L1 retrotransposons that continuously re-enter host-genome.Hence, we investigated the function of ADAR1 in the regulation of L1 activity.By using different cell-culture based retrotransposition assays in HeLa cells, we demonstrated a novel function of ADAR1 as suppressor of L1 retrotransposition. Apparently, this inhibitory mechanism does not occur through ADAR1 editing activity. Furthermore, we showed that ADAR1 binds the basal L1 RNP complex. Overall, these data support the role of ADAR1 as regulator of L1 life cycle., (© The Author(s) 2016. Published by Oxford University Press on behalf of Nucleic Acids Research.)
- Published
- 2017
- Full Text
- View/download PDF
34. Resetting cancer stem cell regulatory nodes upon MYC inhibition.
- Author
-
Galardi S, Savino M, Scagnoli F, Pellegatta S, Pisati F, Zambelli F, Illi B, Annibali D, Beji S, Orecchini E, Alberelli MA, Apicella C, Fontanella RA, Michienzi A, Finocchiaro G, Farace MG, Pavesi G, Ciafrè SA, and Nasi S
- Subjects
- Angiogenesis Inhibitors, Apoptosis, Basic Helix-Loop-Helix Transcription Factors genetics, Cell Differentiation, Cell Proliferation, ErbB Receptors genetics, Glioblastoma physiopathology, Humans, Inhibitor of Differentiation Proteins genetics, MicroRNAs genetics, Nerve Tissue Proteins genetics, Oligodendrocyte Transcription Factor 2, Protein Binding, Transcriptional Activation, Tumor Microenvironment genetics, Zinc Finger E-box-Binding Homeobox 1 genetics, Gene Expression Regulation, Neoplastic, Genes, myc, Glioblastoma genetics, Neoplastic Stem Cells physiology, Peptide Fragments genetics, Proto-Oncogene Proteins c-myc genetics, Transcription Factors genetics
- Abstract
MYC deregulation is common in human cancer and has a role in sustaining the aggressive cancer stem cell populations. MYC mediates a broad transcriptional response controlling normal biological programmes, but its activity is not clearly understood. We address MYC function in cancer stem cells through the inducible expression of Omomyc-a MYC-derived polypeptide interfering with MYC activity-taking as model the most lethal brain tumour, glioblastoma. Omomyc bridles the key cancer stemlike cell features and affects the tumour microenvironment, inhibiting angiogenesis. This occurs because Omomyc interferes with proper MYC localization and itself associates with the genome, with a preference for sites occupied by MYC This is accompanied by selective repression of master transcription factors for glioblastoma stemlike cell identity such as OLIG2, POU3F2, SOX2, upregulation of effectors of tumour suppression and differentiation such as ID4, MIAT, PTEN, and modulation of the expression of microRNAs that target molecules implicated in glioblastoma growth and invasion such as EGFR and ZEB1. Data support a novel view of MYC as a network stabilizer that strengthens the regulatory nodes of gene expression networks controlling cell phenotype and highlight Omomyc as model molecule for targeting cancer stem cells., (© 2016 The Authors.)
- Published
- 2016
- Full Text
- View/download PDF
35. The ADAR1 editing enzyme is encapsidated into HIV-1 virions.
- Author
-
Orecchini E, Federico M, Doria M, Arenaccio C, Giuliani E, Ciafrè SA, and Michienzi A
- Subjects
- Adenosine Deaminase chemistry, Cell Line, Humans, Protein Binding, Protein Interaction Domains and Motifs, RNA-Binding Proteins chemistry, gag Gene Products, Human Immunodeficiency Virus metabolism, Adenosine Deaminase metabolism, HIV-1 physiology, RNA-Binding Proteins metabolism, Virion
- Abstract
Adenosine deaminase acting on RNA1 (ADAR1) was previously reported to affect HIV-1 replication. We report data showing that ADAR1 interacts with the HIV-1 p55 Gag protein, the major structural protein of the immature virus capsid. Furthermore, we found that the endogenous ADAR1 is incorporated into virions purified from the supernatant of primary HIV-1-infected CD4(+) T lymphocytes. Additional experiments demonstrated that the expression of the p55 Gag protein is sufficient for ADAR1 incorporation into virus-like particles (VLPs). Overall, our data originally support the evidence that ADAR1 can be part of the cell protein array uploaded in HIV-1 particles., (Copyright © 2015 Elsevier Inc. All rights reserved.)
- Published
- 2015
- Full Text
- View/download PDF
36. HIV-1 infection causes a down-regulation of genes involved in ribosome biogenesis.
- Author
-
Kleinman CL, Doria M, Orecchini E, Giuliani E, Galardi S, De Jay N, and Michienzi A
- Subjects
- CD4-Positive T-Lymphocytes immunology, Gene Expression Profiling, Humans, Jurkat Cells, RNA Precursors genetics, RNA Processing, Post-Transcriptional genetics, Real-Time Polymerase Chain Reaction, Reproducibility of Results, Sequence Analysis, RNA, Down-Regulation genetics, HIV Infections genetics, HIV Infections immunology, HIV-1 physiology, Ribosomes metabolism
- Abstract
HIV-1 preferentially infects CD4+ T cells, causing fundamental changes that eventually lead to the release of new viral particles and cell death. To investigate in detail alterations in the transcriptome of the CD4+ T cells upon viral infection, we sequenced polyadenylated RNA isolated from Jurkat cells infected or not with HIV-1. We found a marked global alteration of gene expression following infection, with an overall trend toward induction of genes, indicating widespread modification of the host biology. Annotation and pathway analysis of the most deregulated genes showed that viral infection produces a down-regulation of genes associated with the nucleolus, in particular those implicated in regulating the different steps of ribosome biogenesis, such as ribosomal RNA (rRNA) transcription, pre-rRNA processing, and ribosome maturation. The impact of HIV-1 infection on genes involved in ribosome biogenesis was further validated in primary CD4+ T cells. Moreover, we provided evidence by Northern Blot experiments, that host pre-rRNA processing in Jurkat cells might be perturbed during HIV-1 infection, thus strengthening the hypothesis of a crosstalk between nucleolar functions and viral pathogenesis.
- Published
- 2014
- Full Text
- View/download PDF
37. The HIV-1 Tat protein modulates CD4 expression in human T cells through the induction of miR-222.
- Author
-
Orecchini E, Doria M, Michienzi A, Giuliani E, Vassena L, Ciafrè SA, Farace MG, and Galardi S
- Subjects
- CD4 Antigens metabolism, Cell Line, HIV Infections immunology, HIV Infections metabolism, Humans, NF-kappa B metabolism, RNA, Messenger genetics, T-Lymphocyte Subsets immunology, CD4 Antigens genetics, Gene Expression Regulation, HIV Infections genetics, HIV-1 physiology, MicroRNAs genetics, T-Lymphocyte Subsets metabolism, tat Gene Products, Human Immunodeficiency Virus metabolism
- Abstract
Several cellular microRNAs show substantial changes in expression during HIV-1 infection and their active role in the viral life cycle is progressively emerging. In the present study, we found that HIV-1 infection of Jurkat T cells significantly induces the expression of miR-222. We show that this induction depends on HIV-1 Tat protein, which is able to increase the transcriptional activity of NFkB on miR-222 promoter. Moreover, we demonstrate that miR-222 directly targets CD4, a key receptor for HIV-1, thus reducing its expression. We propose that Tat, by inducing miR-222 expression, complements the CD4 downregulation activity exerted by other viral proteins (i.e., Nef, Vpu, and Env), and we suggest that this represents a novel mechanism through which HIV-1 efficiently represses CD4 expression in infected cells.
- Published
- 2014
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.